Literature DB >> 21249606

Testosterone, hemostasis, and cardiovascular diseases in men.

Ellen Brodin1, Torkel Vikan, John-Bjarne Hansen, Johan Svartberg.   

Abstract

Men have a higher incidence of cardiovascular disease (CVD) than women, and adverse thrombotic events increase with age. Recent experimental cross-sectional, and case-control studies have shown that testosterone may affect the hemostatic/fibrinolytic system in men in several ways. It has been hypothesized that physiological doses of testosterone would have a beneficial effect on tissue factor-induced thrombin generation and the development of CVD. The search for eternal youth has created a market for testosterone treatment in aging men during the last few years. However, whether testosterone supplementation could be useful in the treatment of testosterone-deficient elderly men is still controversial. The present review focuses on the coagulation system and CVD from the perspective of testosterone. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249606     DOI: 10.1055/s-0030-1270075

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

Review 1.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

2.  Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study.

Authors:  Harmanpreet Kaur; D Robert Siemens; Angela Black; Sylvia Robb; Spencer Barr; Charles H Graham; Maha Othman
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  Comparison Between Thromboelastography and Conventional Coagulation Tests in Surgical Patients With Localized Prostate Cancer.

Authors:  Zhengwei Wang; Jing Li; Qingwei Cao; Lei Wang; Fengzhi Shan; Houyi Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-05       Impact factor: 2.389

4.  An expression signature at diagnosis to estimate prostate cancer patients' overall survival.

Authors:  Z Peng; L Skoog; H Hellborg; G Jonstam; I-L Wingmo; M Hjälm-Eriksson; U Harmenberg; G C Cedermark; K Andersson; L Ahrlund-Richter; S Pramana; Y Pawitan; M Nistér; S Nilsson; C Li
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-07       Impact factor: 5.554

5.  Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.

Authors:  Yu-Chuan Lu; Chao-Yuan Huang; Huei-Ming Yeh; Jian-Hua Hong; Chao-Hsiang Chang; Chih-Hsin Muo; Shiu-Dong Chung; Teng-Kai Yang; Fu-Shan Jaw; Chi-Jung Chung
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

6.  Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.

Authors:  Luuk J J Scheres; Nienke L D Selier; Nienke M Nota; Jeske J K van Diemen; Suzanne C Cannegieter; Martin den Heijer
Journal:  J Thromb Haemost       Date:  2021-02-22       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.